According to a recent LinkedIn post from Beacon Therapeutics, the company presented a 12‑month safety and efficacy update from its Phase 2 DAWN trial of lead gene therapy candidate laru-zova in X-linked retinitis pigmentosa at the ARVO 2026 meeting in Denver. The post indicates that laru-zova was generally well tolerated through month 12 and that participants showed sustained improvements across several measures of visual function.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post also notes that topline data from the pivotal VISTA trial are expected in the second half of 2026, positioning that readout as the next major clinical inflection point for the program. For investors, the reported durability and safety profile in Phase 2 may support confidence in the underlying mechanism and market potential in an inherited blinding retinal disease, while the VISTA timeline highlights a key upcoming catalyst that could influence valuation and partnering or fundraising prospects.